MRI Background Parenchymal Enhancement as a Risk Factor for Breast Cancer: The IMAGINg and Epidemiology (IMAGINE) Study



Status:Active, not recruiting
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:21 - 69
Updated:10/31/2018
Start Date:November 2014
End Date:November 2019

Use our guide to learn which trials are right for you!

The purpose of the study is to view what normal breast tissue looks like on an MRI and
mammogram to help determine how it may affect the risk of developing breast cancer. The
investigators will also compare the information collected from the questionnaire and medical
records to help better understand how this may affect the risk of developing breast cancer.
If a saliva or tissue sample is collected for future use, this information will enable us to
study genetic risk factors as well.

Proposed Study Methods Pertaining to the Population, Eligibility and Recruitment In this
multi-center hospital-based case-control study, cases will be women diagnosed with incident
breast cancer who have undergone or are about to undergo a bilateral breast MRI with contrast
to assess extent of disease. The cancer-free controls will be women at high-risk of breast
cancer undergoing a bilateral breast MRI with contrast for screening. The MRI collected for
the study may be post-biopsy and post-surgery (unilateral lumpectomy/mastectomy), but prior
to bilateral mastectomy, radiation, hormonal, and/or chemotherapy. Study participants also
need to have a bilateral mammogram available at the study site within 24 months prior to, or
up to 24 months after the study MRI (as long as prior to surgery, radiation, hormonal, and/or
chemotherapy), to be included in the secondary aim analysis. The MRI/mammogram selected for
this study do not need to be conducted at the recruitment site, the digital images just need
to be accessible from the patient medical records at the site. Questionnaire data, optional
saliva samples, MRIs, mammograms, and medical records will be collected over a 27 month
period from women at three NCI-designated comprehensive cancer centers (MSK, Penn, Utah).
Each site has demonstrated experience with recruitment, patient interviews and collection of
MRIs and mammograms.

Inclusion Criteria:

- Eligibility Criteria for Breast Cancer Cases (invasive)

Women with the following characteristics at MRI will be eligible as invasive cases:

1. have a diagnosed invasive unilateral breast cancer after 1/1/2010;

2. have a pre-treatment (prior to bilateral mastectomy, radiation, hormonal, and/or
chemotherapy) bilateral breast MRI with contrast available from the study site;

3. be ≥ 21 and <70 years old at time of diagnosis; and

4. have an intact contralateral breast at the time of study MRI.

Eligibility Criteria for Breast Cancer Cases (non-invasive)

Women with the following characteristics at MRI will be eligible as non-invasive cases:

have a diagnosed unilateral ductal carcinoma in situ (DCIS) preferably after 1/1/2013; 2)
have a pre-treatment (prior to bilateral mastectomy, radiation, hormonal, and/or
chemotherapy) bilateral breast MRI with contrast available from the study site; 3) be ≥ 21
and <70 years old at time of diagnosis; and 4) have an intact contralateral breast. The
contralateral breast needs to be intact and unaffected by an invasive carcinoma and/or DCIS
so the MRI reading can be done on the breast without cancer. Women with a history of
previous cancer diagnosis are excluded because treatment they may have received for these
cancers might affect the MRI readings.

Eligibility Criteria for Controls Controls will be women determined to be at high risk of
developing breast cancer (i.e., lifetime risk ≥20%

Controls must meet the following criteria:

1. have a bilateral breast MRI screening with contrast available from the study site;

2. be ≥ 21 and <70 years old at time of MRI; and

3. negative breast MRI screen.

Exclusion Criteria:

- For either cases or controls prior to study MRI date:

1. unable to speak and read English;

2. history of prophylactic mastectomy;

3. history of pre-pectoral breast implants in either breast (sub-pectoral are
acceptable);

4. history of breast reduction surgery;

5. currently taking, or in the previous 3 months: hormonal medication such as
Tamoxifen (Nolvadex), Raloxifene (Evista), aromatase inhibitors
(Anastrozole/Arimidex, Letrozole/Femara, and/or Exemestane/Aromasin); and/or
other postmenopausal hormonal therapy (PHT) medication; and/or hormonal
medication for fertility treatment; [Note: Women are INELIGIBLE if they report
taking pills orally, use a patch or ring, even if just intermittently used. Women
are ELIGIBLE if they report just taking hormone replacement therapy in the form
of a cream, suppository (or intra-vaginal), soy-based, or other natural product.]

6. currently, or in the preceding 6 months, pregnant or breast feeding; and

7. history of previous cancer including DCIS [Note: Women are ELIGIBLE if diagnosed
with non melanoma skin cancer lobular carcinoma in situ (LCIS) and/or cervical
cancer in situ ].

Notes: Women recently diagnosed with DCIS within the study period will be categorized as
non-invasive cases (preferable prospective recruitment only). Only one breast may be
affected by a recent diagnosis of invasive carcinoma and/or DCIS.
We found this trial at
7
sites
Basking Ridge, New Jersey
Phone: 646-888-8241
?
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
201 Presidents Circle
Salt Lake City, Utah 84108
801) 581-7200
Phone: 801-213-4269
University of Utah Research is a major component in the life of the U benefiting...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Commack, New York 11725
Phone: 646-888-8241
?
mi
from
Commack, NY
Click here to add this to my saved trials
500 Westchester Avenue
Harrison, New York 10604
Phone: 646-888-8241
?
mi
from
Harrison, NY
Click here to add this to my saved trials
Middletown, New Jersey 07748
Phone: 646-888-8241
?
mi
from
Middletown, NJ
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Jonine Bernstein, PhD
Phone: 646-888-8241
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials